Yahoo
Frankfurt - Delayed Quote EUR

SCHOTT Pharma AG & Co. KGaA (1SXP.F)

25.20 +0.10 (+0.40%)
At close: October 30 at 8:00:44 AM GMT+1

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
Name Title Pay Exercised Year Born
Mr. Christian Mias
Chief Executive Officer -- -- 1974
Mr. Reinhard Josef Mayer
CFO & Member of Management Board of SCHOTT Pharma Management AG -- -- 1967
Mr. Tobias Erfurth
Head of Investor Relations -- -- --
Isabelle Jeangoudoux
Head of Global Product Management -- -- --
Dr. Arne Kloke
Head of Service & Sustainability Management -- -- --

SCHOTT Pharma AG & Co. KGaA

Hattenbergstrasse 10
Mainz, 55122
Germany
49 6131 66 0 https://www.schott-pharma.com
Sector: 
Healthcare
Full Time Employees: 
5,002

Description

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.

Corporate Governance

SCHOTT Pharma AG & Co. KGaA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

December 10, 2026 at 9:00 PM UTC

SCHOTT Pharma AG & Co. KGaA Earnings Date

Recent Events

February 4, 2026 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: